BACKGROUND: The clinical profile of @entity299 ( @entity299 ) recipients has changed in recent years. Nowadays, we have to deal with a higher number of co-morbidities, including @entity1095 ( @entity1095 ). Previous studies suggest an increase in post- @entity299 morbidity and mortality associated with @entity1095 , especially when it is symptomatic. Our study aims were to analyze the prognostic implications of the presence of @entity1095 before transplantation and to determine the factors associated with its development after it. METHODS: @entity299 @entity1 (n  = 217) who survived the first year after surgery were included in the study. Mean follow-up was 9    5 years. RESULTS: There were no statistically significant differences in mortality rates between @entity1 with @entity1095 (before or after @entity299 ) and those without. One third of @entity1 with @entity1095 required surgery in the post- @entity299 monitoring, either revascularization or amputation. Furthermore, the prevalence of @entity1095 was doubled. @entity2299 before @entity299 (odds ratio [OR]: 2.9, 95% confidence interval [CI]: 1.3-6.4; P  <  .01) and older recipient age (OR: 1.05, 95% CI: 1.01-1.09; P  < .05) were independently associated with development of @entity1095 by means of multivariate analysis. CONCLUSIONS: The presence of @entity1095 must be evaluated individually in candidates for @entity299 despite being a relative contraindication to it at the present time.

Role of Vascular Disease in the Evolution of Heart Transplant XXXX .

@entity1095 :: ('MESH:D016491', 'Disease') :: ['PVD', 'peripheral vascular disease'] @entity1 :: ('9606', 'Species') :: ['patients'] @entity2299 :: ('MESH:D050171', 'Disease') :: ['Dyslipidemia'] @entity299 :: ('MESH:D006331', 'Disease') :: ['HT', 'heart transplantation']
@entity1 :: (9606,Species) :: ['Patients']
